Form 8-K VERTEX PHARMACEUTICALS For: Jul 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vertex (VRTX) PT Raised to $203 at RBC Capital
July 26, 2018 8:44 AM EDTRBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $203.00 (from $202.00) while maintaining an Outperform rating.
Analyst Brian Abrahams commented, "Despite rising expectations into 2Q, an impressive beat for VRTX's CF franchise."
... MoreVertex (VRTX) PT Raised to $204 at BMO Capital; 'Stellar Revenue'
July 26, 2018 7:11 AM EDTBMO Capital raised its price target on Vertex (NASDAQ: VRTX) to $204.00 (from $191.00) while maintaining an Outperform rating following results.
Analyst Do Kim commented, "We raise our revenue estimates and target price to $204 from $191, following stellar 2Q18 CF revenues that easily exceeded our and... More
